Two monoclonal antibodies (249F8 and 278A9) to ouabain were produced by somatic cell fusion. They reacted in dose-dependent manners with ouabain and digoxin.
INTRODUCTION
Ouabain, digoxin and other cardiac glycosides have been clinically used as cardiotonics.
The utility of anti-digoxin antibodies in therapeutic and diagnostic use has been well recognized. Increased levels of an endogenous digoxin-like factor (EDF), an inhibitor of Na + , K + -ATPase, have been found in the plasma of experimental hypertensive animals and of humans with essential hypertension (1) . Many studies about EDF have been performed (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . In these studies, the Na + , K + -ATPase inhibitory activity, the immuno-*Address reprint requests to Dr. Yoshitake Terano, 3-4-17, Asahigaoka, reactivity to anti-digoxin antibodies and displacing the activity of ouabain from its receptor have been used as the spcific characters of EDF. There are reports on production of polyclonal (14) and monoclonal (15) (16) (17) antibodies to digoxin, but no report mentions the structure of the site recognized by the antibodies. In 1985, we produced polyclonal antibodies reacting with ouabain and digoxin (2) . We, therefore, produced monoclonal antibodies to ouabain as a tool for studying EDF and speculated the structure of the site recognized by the antibodies
MATERIALS AND METHODS
Regents: The reagents used are listed in Table I . [*]The procedure for preparation of this compound is described in Method [2] Preparation of ouabain-bound bovine serum albumin (Oua-BSA): Ouabain (0.20 mmol) and sodium periodate (0.25 mmol) were dissolved in 5.0 ml of distilled water. After standing for 24 hr at 4 C, 10 ml of ethanol was added and the pH was adjusted to 8.35 by the addition of NaOH. Then, 0.002 mmol bovine serum albumin (BSA) was added and the pH was readjusted to 9.35 with NaOH.
After standing overnight at 4 C, sodium cyanoborohydride (0.8 mmol) was added and the solution was dialyzed against flowing tap water for 48 hr. The solution was lyophylized after re-dialyses (three times) against distilled water. Spectrophotometry at 370 nm in 50% H2SO4 revealed that 33 mol of ouabain had bound to one mol of BSA.
Immunization and somatic cell fusion: An emulsion composed of a mixture of Freund's complete adjuvant (Calbiochem-Behring Corp., La Jolla, CA) and Oua-BSA (0.1 ng/ml) was injected subcutaneously and intraperitoneally to fiveweek-old female BALB/c mice (0.02 mg/mouse). Furthermore, three, six and nine weeks later, the mice were boosted intraperitoneally with an emulsion composed of a mixture of Freund's incomplete adjuvant (Difco Laboratories, Detroit, MI) and Ou-BSA(0.01 mg/mouse).
Three days before cell fusion, mice received intravenously Oua-BSA (0.02 mg/mouse) in saline. Splenocytes from the immunized mice were mixed with 8-azaguanine-resistant murine myeloma cells, designated P3-X63-Ag8. U1 (P3U1), at a ratio of 10:1 and fused by a modification of the procedure described by Koehler and Milstein (18) .
Selection by hypoxanthine aminopterin thymidine medium (HAT medium) and cloning: The fused cells were cultured in HAT medium and screened with the naked eye for cell growth. The culture media were screened for anti-ouabain antibody by ELISA (described afterward).
Hybridoma cell populations secreting anti-ouabain antibody were identified by ELISA and cloned by limiting dilution on feeder layers of murine thymocytes.
Amplification and purification of hybridoma proteins: Each cloned hybridoma cell line was grown in tissue culture and amplified in the ascites form in pristane (2,6,10,14-tetramethyldecanoic acid)-primed BALB/c mice. Murine IgG containing ouabain-specific antibodies were purified from ascites fluid by affinity chromatography on a protein G-Sepharose gel after salting out with 50% saturated (NH4)25O4 (pH 7.4) and depletion of lipids with trichlorotrifluoroethane.
Enzyme-linked immunosorbent assay (ELISA): (a) Procedure for ELISA.
Digoxin (dissolved in 60% ethanol) was diluted in 0.1 M sodium bicarbanate buffer (pH 9.6) to a concentration of 0.01 mg/ml, and 0.1 ml was added to each well of a 96-well microtiter plate (Coster 3590, Costar Corporation, Cambridge, MA). The plate was incubated for 1 hr at 37 C and the solution was removed.
After washing with phosphate buffered saline (PBS) containing 0.1% NaN3 and 0.1% Tween 20 (PBS-T), the residual protein-binding sites were blocked with phosphate buffered saline containing 1% gelatin for 30 min at 37 C. The plate was washed with PBS-T and 0.1 ml of a sample solution was added to each well. After incubation for 1 hr at 37 C and washing with PBS-T, 0.1 ml of 1:500 diluted biotinylated sheep anti-mouse Ig antibody (RPN 1021, Amersham, International plc., Amersham, UK) was added to each well. The plate was incubated for 1 hr at 37 C and washed with PBS-T.
After washing, 0.1 ml of 1:500 diluted alkaline phosphatase-conjugated avidin (D365, Dakopatts als, Glostrup, Denmark) was added to each well and the plate was incubated for 30 min at 37 C. The plate was washed with PBS-T and 0.1 ml of p-nitrophenyl phosphate disodium salt (0.25 mM or, 1 mg/ml) containing MgC12 (0.5 mM) in diethanolamine buffer (10 mM) pH 9.5 was added to each well. After incubation at room temperature until the desired color intensity was achieved, 0.05 ml of 3 N NaOH was added to stop the reaction.
The absorbance at 405 nm of the water soluble yellow reaction product was measured with a microplate autoreader (MR580, Dynatec Laboratories Inc., Alexandria, VA).
(b) Application of ELISA. Selection of hybridomas producing specific antibodies to ouabain was performed by ELISA in the plates coated with ouabain-BSA, digoxin, or BSA, and hybridomas secreting antibodies with reactivity not for BSA but for ouabain-BSA and digoxin were selected. The ouabain-coated ELISA plate was not usable because enough ouabain was not adsorbed on an ELISA plate.
Class and subclass typing was performed by the same procedure as described above with biotinylated goat IgG anti-mouse antibodies for each class, subclass and type (Amersham International plc.) instead of biotinylated sheep IgG anti-mouse Ig antibody.
The cross reactivities of monoclonal antibodies to various substances were examined by ELISA using solutions containing appropriate amounts of antibody and a tested substance that had been incubated for 1 hr at 37 C.
The quantitative reactivity of ouabain and digoxin to monoclonal antibodies was also examined by ELISA with the same sample treatment as the cross reactivity test.
Assay for Na +, K+ -ATPase inhibitory activity: The reaction mixture (2.7 ml) contained 40 mM N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES)-NaOH buffer (pH 7.4), 100 mM NaCI, 4.5 mM MgSO4, 5 mM EGTA, 0.02% n-octylglucoside, 0.56 mM vanadium free ATP (Sigma Chemical Co.), 0.05 units canine kidney Na + , K + -ATPase (Sigma Chemical Co.), and 10-6 M of sample substance. Different KC1 concentrations (0.1 mM and 10 mM) were used to distinguish between ouabain-like and non-ouabain like inhibition types since ouabain inhibits Na + , K + -ATPase by a competitive mode against K + (19) . The enzyme reaction was initiated by the addition of ATP at 25 C and the reaction mixture was incubated for 10 min when the assay mixture contained 10 mM KC1 or for 30 min when it contained 0.1 ml KC1. The reaction was stopped by the addition of 0.33 ml of a 6 N H2SO4 solution containing 2.5% ammonium molybdate and 0.1% Triton X-100; polyoxyethylene octyl phenyl ether (Wako Pure Chemicals Co., Osaka). 
Cross Reactivity of Monoclonal Antibodies
Analysis for the partial structure of ouabain recognized by the MAbs was performed by ELISA (antibody capture assay), using various cardiac glycosides, other compounds that have the partial structure of ouabain and various substances (3-6) isolated until now as EDF. Each MAb and a substance which was examined for its cross reactivity with a MAb were precedently allowed to react, and the amount of residual unreacted antibody was measured by ELISA in a digoxin-coated plate. All substances tested for the cross reactivities with 249F8 and 278A9 are listed in [*] Inhibition of Na + , K + -ATPase activity was tested with this substance. The suggested structure recognized by MAbs is shown in Fig. 3(b) .
Inhibition of Sodium Potassium ATPase Activity A neutralizing ability of these MAbs on the pharmacological effects of cardiac glycosides was assumed by the results of both the cross reactivity test and the assay for Na + , K + -ATPase inhibitory activity. As it was impossible to detect the inhibition by adding MAbs directry to the ouabain-ATPase mixture because of apparent inhibition by MAbs themselves, the neutralizing ability was presumed by comparing the chemical structures recognized by MAbs and represented by the Na + , K + -ATPase inhibitory activity. The Na + , K + -ATPase inhibitory activity was examined in those substances marked [*] in Table II . Cross reactivity of substances listed in Table I with monoclonal  antibodies. 249F8 and 278A9 were examined by ELISA (antibody capture assay) as described in Materials and Methods.
As shown in Table N , cardiac glycosides and their genins inhibited Na+, K + -ATPase by competing against K+. They also had the structure shown in Fig.   3 (b) . The relationships among the ouabain-like Na + , K + -ATPase inhibitory activity, the cross reactivity with the MAbs and the chemical structure shown in Fig. 3(b) are listed in Table V . The numbers in ( ) are the same as those (1)- (14) in Table II . of the Na +, K + -ATPase inhibitory activity and, cross reactivity with monoclonal antibodies with the possession of the structure shown in Fig. 3(b Moreover, it can be considered that the chemical structure of the site with Na + , K + -ATPase inhibitory activity is an important base for synthesis of novel medicines with cardiac glycoside-like effects.
As stated in the introduction, many studies have been performed on endogenous digoxin-like factors (EDF) on an assumption that the cross reactivity with anti-digoxin antibody is one of the specific character of EDF (2-13).
Though several substances (4-6) have been isolated as EDF, they did not react with MAbs (249F8 and 278A9). Some monoclonal antibodies to digoxin (15) (16) (17) have been produced, but the structure recognized by those MAbs have not been elucidated. The well characterized monoclonal antibodies (249F8 and 278A9) obtained here will be of great use as probes for studying the putative endogenous digoxin-like factor.
